Highlights:
-
GAAP income from continuing operations of $88 million, or $0.26 per
share
-
Non-GAAP income from continuing operations of $129 million, or $0.38
per share(1)
-
Orders of $1.04 billion and revenues of $963 million
-
Third-quarter fiscal year 2015 revenue guidance of $995 million to
$1.015 billion, and non-GAAP earnings guidance of $0.38 to $0.42 per
share(2)
-
Fiscal year 2015 revenue guidance of $4.05 billion to $4.11 billion,
and non-GAAP earnings guidance of $1.67 to $1.73 per share(2)
SANTA CLARA, Calif.--(BUSINESS WIRE)--May 18, 2015--
Agilent Technologies Inc. (NYSE: A) today reported orders of $1.04
billion, up 1 percent (up 8 percent adjusted for currency) over one year
ago for the second fiscal quarter ended April 30, 2015. Second-quarter
revenues were $963 million, down 3 percent (up 4 percent adjusted for
currency(3)) compared with one year ago.
Second-quarter GAAP income from continuing operations was $88 million,
or $0.26 per share. Last year’s second-quarter GAAP income from
continuing operations was $40 million, or $0.12 per share.
During the second quarter, Agilent had intangible amortization of $38
million, business exit and divestiture costs of $10 million,
transformation costs of $17 million and a tax benefit of $24 million.
Excluding these items, Agilent reported second-quarter adjusted income
from continuing operations of $129 million, or $0.38 per share(1).
“Agilent delivered solid earnings within guidance, along with excellent
order momentum in the second quarter,” said Mike McMullen, Agilent
president and CEO. “Our continued focus on customers and strong market
acceptance of our new products and sales structure are driving order
growth.”
“We continue to make progress on streamlining our company,” he added.
“We delivered an adjusted operating margin of 18.3 percent(4),
up 140 basis points. We are well positioned to deliver on our core
growth and earnings guidance for the year.”
Second-quarter revenues of $473 million from Agilent’s Life Sciences and
Applied Markets Group (LSAG) declined 5 percent year over year (up 1
percent adjusted for currency(3)). LSAG saw strong order
growth but was unable to convert all of this order strength to revenue
in the quarter. LSAG’s Q2 operating margin was 15.8 percent.
Q2 revenues of $321 million from the Agilent CrossLab Group (ACG)
declined 1 percent year over year (up 7 percent adjusted for currency(3)).
Growth continued to be strong across Agilent’s analytical services and
consumables business. ACG’s operating margin was 21.5 percent in the
quarter.
The Diagnostics and Genomics Group (DGG) Q2 revenues of $169 million
rose 1 percent year over year (up 10 percent adjusted for currency(3)),
led by particular strength in Dako and the nucleic acid businesses.
DGG’s operating margin for the quarter was 15.0 percent.
Agilent’s third-quarter 2015 revenues are expected to be in the range of
$995 million to $1,015 million. Third-quarter non-GAAP earnings are
expected to be in the range of $0.38 to $0.42 per share(2).
For fiscal year 2015, Agilent expects revenues of $4.05 billion to $4.11
billion and non-GAAP earnings of $1.67 to $1.73 per share(2).
The guidance is based on April 30, 2015 exchange rates. Foreign currency
movements continue to impact Agilent’s revenues and profits, and the
company has taken action on multiple fronts to mitigate the effects.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A), a global leader in life sciences,
diagnostics and applied chemical markets, is the premier laboratory
partner for a better world. Agilent works with customers in more than
100 countries, providing instruments, software, services and consumables
for the entire laboratory workflow. Agilent generated revenues of $4.0
billion in fiscal 2014. The company employs about 12,000 people
worldwide. Information about Agilent is available at www.agilent.com.
Agilent’s management will present more details about its second-quarter
FY2015 financial results on a conference call with investors today at
1:30 p.m. PT. This event will be webcast live in listen-only mode.
Listeners may log on at www.investor.agilent.com
and select “Q2 2015 Agilent Technologies Inc. Earnings Conference Call”
in the “News & Events Calendar of Events” section. The webcast will
remain available on the company’s website for 90 days.
Additional information regarding financial results can be found at www.investor.agilent.com
by selecting “Financial Results” in the “Financial Information” section.
A telephone replay of the conference call will be available at
approximately 5:30 p.m. PT today through May 25 by dialing +1 855 859
2056 (or +1 404 537 3406 from outside the United States) and entering
passcode 22310408.
Forward-Looking Statements
This news release contains forward-looking statements as defined in the
Securities Exchange Act of 1934 and is subject to the safe harbors
created therein. The forward-looking statements contained herein
include, but are not limited to, information regarding Agilent’s future
revenues, earnings and profitability; planned new products; market
trends; the future demand for the company’s products and services;
customer expectations; and revenue and non-GAAP earnings guidance for
the third quarter and full fiscal year 2015. These forward-looking
statements involve risks and uncertainties that could cause Agilent’s
results to differ materially from management’s current expectations.
Such risks and uncertainties include, but are not limited to, unforeseen
changes in the strength of our customers’ businesses; unforeseen changes
in the demand for current and new products, technologies, and services;
unforeseen changes in the currency markets; customer purchasing
decisions and timing, and the risk that we are not able to realize the
savings expected from integration and restructuring activities.
In addition, other risks that Agilent faces in running its operations
include the ability to execute successfully through business cycles; the
ability to meet and achieve the benefits of its cost-reduction goals and
otherwise successfully adapt its cost structures to continuing changes
in business conditions; ongoing competitive, pricing and gross-margin
pressures; the risk that our cost-cutting initiatives will impair our
ability to develop products and remain competitive and to operate
effectively; the impact of geopolitical uncertainties and global
economic conditions on our operations, our markets and our ability to
conduct business; the ability to improve asset performance to adapt to
changes in demand; the ability of our supply chain to adapt to changes
in demand; the ability to successfully introduce new products at the
right time, price and mix; the ability of Agilent to successfully
integrate recent acquisitions; the ability of Agilent to successfully
comply with certain complex regulations; and other risks detailed in
Agilent’s filings with the Securities and Exchange Commission, including
our quarterly report on Form 10-Q for the quarter ended Jan. 31, 2015.
Forward-looking statements are based on the beliefs and assumptions of
Agilent’s management and on currently available information. Agilent
undertakes no responsibility to publicly update or revise any
forward-looking statement.
|
|
|
(1)
|
|
Non-GAAP income from continuing operations and non-GAAP income from
continuing operations per share exclude primarily the impacts of
acquisition and integration costs, pre-separation costs,
transformation initiatives and restructuring costs, business exit
and divestiture costs, and non-cash intangibles amortization. We
also exclude any tax benefits that are not directly related to
ongoing operations and which are either isolated or cannot be
expected to occur again with any regularity or predictability. A
reconciliation between non-GAAP net income and GAAP net income is
set forth on page 6 of the attached tables along with additional
information regarding the use of this non-GAAP measure.
|
|
|
|
|
|
|
|
|
|
(2)
|
|
Non-GAAP earnings per share as projected for Q3 FY15 and full fiscal
year 2015 excludes primarily the impact of acquisition and
integration costs, future restructuring costs, asset impairment
charges, business exit and divestiture costs and non-cash
intangibles amortization. We also exclude any tax benefits that are
not directly related to ongoing operations and which are either
isolated or cannot be expected to occur again with any regularity or
predictability. Most of these excluded amounts pertain to events
that have not yet occurred and are not currently possible to
estimate with a reasonable degree of accuracy. Therefore, no
reconciliation to GAAP amounts has been provided. Future
amortization of intangibles is expected to be approximately $40
million per quarter.
|
|
|
|
|
|
|
|
|
|
(3)
|
|
Revenue excluding the impact of currency is a non-GAAP measure. A
reconciliation between GAAP revenue and non-GAAP revenue is set
forth on page 8 of the attached tables along with additional
information regarding the use of this non-GAAP measure.
|
|
|
|
|
|
|
|
|
|
(4)
|
|
Adjusted operating margin is a non-GAAP measure and excludes
primarily the impacts of acquisition and integration costs,
transformation initiatives and restructuring costs, business exit
and divestiture costs, and non-cash intangibles amortization in
addition to the costs related to services Agilent is providing to
Keysight post separation. A reconciliation is set forth on page 9 of
the attached tables along with additional information regarding the
use of this non-GAAP measure.
|
|
|
|
|
|
|
|
NOTE TO EDITORS: Further technology, corporate citizenship and
executive news is available on the Agilent news site at www.agilent.com/go/news.
|
|
|
|
AGILENT TECHNOLOGIES, INC.
|
|
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
|
|
(In millions, except per share amounts)
|
|
(Unaudited)
|
|
PRELIMINARY
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
|
|
April 30,
|
|
Percent
|
|
|
|
|
2015
|
|
|
|
2014
|
|
|
Inc/(Dec)
|
|
|
|
|
|
|
|
|
|
Orders
|
|
$
|
1,039
|
|
|
$
|
1,031
|
|
|
1
|
%
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
$
|
963
|
|
|
$
|
988
|
|
|
(3
|
%)
|
|
|
|
|
|
|
|
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
Cost of products and services
|
|
|
483
|
|
|
|
503
|
|
|
(4
|
%)
|
|
Research and development
|
|
|
81
|
|
|
|
87
|
|
|
(7
|
%)
|
|
Selling, general and administrative
|
|
|
292
|
|
|
|
304
|
|
|
(4
|
%)
|
|
Total costs and expenses
|
|
|
856
|
|
|
|
894
|
|
|
(4
|
%)
|
|
|
|
|
|
|
|
|
|
Income from operations
|
|
|
107
|
|
|
|
94
|
|
|
14
|
%
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
2
|
|
|
|
2
|
|
|
—
|
|
|
Interest expense
|
|
|
(17
|
)
|
|
|
(30
|
)
|
|
(43
|
%)
|
|
Other income (expense), net
|
|
|
4
|
|
|
|
3
|
|
|
33
|
%
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before taxes
|
|
|
96
|
|
|
|
69
|
|
|
39
|
%
|
|
|
|
|
|
|
|
|
|
Provision for income taxes
|
|
|
8
|
|
|
|
29
|
|
|
(72
|
%)
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
88
|
|
|
|
40
|
|
|
120
|
%
|
|
|
|
|
|
|
|
|
|
Income (loss) from discontinued operations, net of tax
|
|
|
(5
|
)
|
|
|
99
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
83
|
|
|
$
|
139
|
|
|
(40
|
%)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share - Basic:
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
0.26
|
|
|
$
|
0.12
|
|
|
|
|
Income (loss) from discontinued operations
|
|
$
|
(0.01
|
)
|
|
$
|
0.30
|
|
|
|
|
Net income per share - Basic
|
|
$
|
0.25
|
|
|
$
|
0.42
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share - Diluted:
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
0.26
|
|
|
$
|
0.12
|
|
|
|
|
Income (loss) from discontinued operations
|
|
$
|
(0.01
|
)
|
|
$
|
0.29
|
|
|
|
|
Net income per share - Diluted
|
|
$
|
0.25
|
|
|
$
|
0.41
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing net income per share:
|
|
|
|
|
|
|
|
Basic
|
|
|
334
|
|
|
|
333
|
|
|
|
|
Diluted
|
|
|
337
|
|
|
|
337
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash dividends declared per common share
|
|
$
|
0.100
|
|
|
$
|
0.132
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The preliminary income statement is estimated based on our current
information.
|
|
|
|
|
|
Page 1
|
|
|
|
AGILENT TECHNOLOGIES, INC.
|
|
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
|
|
(In millions, except per share amounts)
|
|
(Unaudited)
|
|
PRELIMINARY
|
|
|
|
|
|
|
|
Six Months Ended
|
|
|
|
|
|
April 30,
|
|
Percent
|
|
|
|
|
2015
|
|
|
|
2014
|
|
|
Inc/(Dec)
|
|
|
|
|
|
|
|
|
|
Orders
|
|
$
|
2,034
|
|
|
$
|
2,010
|
|
|
1
|
%
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
$
|
1,989
|
|
|
$
|
1,996
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
Cost of products and services
|
|
|
996
|
|
|
|
1,001
|
|
|
—
|
|
|
Research and development
|
|
|
169
|
|
|
|
175
|
|
|
(3
|
%)
|
|
Selling, general and administrative
|
|
|
602
|
|
|
|
602
|
|
|
—
|
|
|
Total costs and expenses
|
|
|
1,767
|
|
|
|
1,778
|
|
|
(1
|
%)
|
|
|
|
|
|
|
|
|
|
Income from operations
|
|
|
222
|
|
|
|
218
|
|
|
2
|
%
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
4
|
|
|
|
4
|
|
|
—
|
|
|
Interest expense
|
|
|
(33
|
)
|
|
|
(59
|
)
|
|
(44
|
%)
|
|
Other income (expense), net
|
|
|
16
|
|
|
|
3
|
|
|
433
|
%
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before taxes
|
|
|
209
|
|
|
|
166
|
|
|
26
|
%
|
|
|
|
|
|
|
|
|
|
Provision for income taxes
|
|
|
19
|
|
|
|
5
|
|
|
280
|
%
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
190
|
|
|
|
161
|
|
|
18
|
%
|
|
|
|
|
|
|
|
|
|
Income (loss) from discontinued operations, net of tax
|
|
|
(35
|
)
|
|
|
173
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
155
|
|
|
$
|
334
|
|
|
(54
|
%)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share - Basic:
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
0.57
|
|
|
$
|
0.48
|
|
|
|
|
Income (loss) from discontinued operations
|
|
$
|
(0.11
|
)
|
|
$
|
0.52
|
|
|
|
|
Net income per share - Basic
|
|
$
|
0.46
|
|
|
$
|
1.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share - Diluted:
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
0.56
|
|
|
$
|
0.48
|
|
|
|
|
Income (loss) from discontinued operations
|
|
$
|
(0.10
|
)
|
|
$
|
0.51
|
|
|
|
|
Net income per share - Diluted
|
|
$
|
0.46
|
|
|
$
|
0.99
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing net income per share:
|
|
|
|
|
|
|
|
Basic
|
|
|
335
|
|
|
|
333
|
|
|
|
|
Diluted
|
|
|
337
|
|
|
|
338
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash dividends declared per common share
|
|
$
|
0.200
|
|
|
$
|
0.264
|
|
|
|
|
|
|
|
|
The preliminary income statement is estimated based on our current
information.
|
|
|
|
|
|
Page 2
|
|
|
|
AGILENT TECHNOLOGIES, INC.
|
|
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
|
|
(In millions)
|
|
(Unaudited)
|
|
PRELIMINARY
|
|
|
|
|
|
|
|
Three Months Ended
|
|
Six Months Ended
|
|
|
|
April 30,
|
|
April 30,
|
|
|
|
|
2015
|
|
|
|
2014
|
|
|
|
2015
|
|
|
|
2014
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
83
|
|
|
$
|
139
|
|
|
$
|
155
|
|
|
$
|
334
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income (loss), net of tax:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized gain on investments
|
|
|
—
|
|
|
|
3
|
|
|
|
—
|
|
|
|
—
|
|
|
Unrealized gain (loss) on derivative instruments
|
|
|
(1
|
)
|
|
|
1
|
|
|
|
6
|
|
|
|
(1
|
)
|
|
Amounts reclassified into earnings related to derivative instruments
|
|
|
(5
|
)
|
|
|
—
|
|
|
|
(8
|
)
|
|
|
—
|
|
|
Foreign currency translation
|
|
|
(6
|
)
|
|
|
88
|
|
|
|
(271
|
)
|
|
|
33
|
|
|
Net defined benefit pension cost and post retirement plan costs:
|
|
|
|
|
|
|
|
|
|
Change in actuarial net loss
|
|
|
6
|
|
|
|
12
|
|
|
|
10
|
|
|
|
25
|
|
|
Change in net prior service benefit
|
|
|
(3
|
)
|
|
|
(8
|
)
|
|
|
(5
|
)
|
|
|
(16
|
)
|
|
Other comprehensive income (loss)
|
|
|
(9
|
)
|
|
|
96
|
|
|
|
(268
|
)
|
|
|
41
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive income (loss)
|
|
$
|
74
|
|
|
$
|
235
|
|
|
$
|
(113
|
)
|
|
$
|
375
|
|
|
|
|
|
|
The preliminary statement of comprehensive income is estimated based
on our current information.
|
|
|
|
|
|
Page 3
|
|
|
|
AGILENT TECHNOLOGIES, INC.
|
|
CONDENSED CONSOLIDATED BALANCE SHEET
|
|
(In millions, except par value and share amounts)
|
|
(Unaudited)
|
|
PRELIMINARY
|
|
|
|
|
|
|
|
April 30,
|
|
October 31,
|
|
|
|
|
2015
|
|
|
|
2014
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
2,197
|
|
|
$
|
2,218
|
|
|
Accounts receivable, net
|
|
|
576
|
|
|
|
626
|
|
|
Inventory
|
|
|
556
|
|
|
|
574
|
|
|
Other current assets
|
|
|
291
|
|
|
|
261
|
|
|
Current assets of discontinued operations
|
|
|
—
|
|
|
|
1,821
|
|
|
Total current assets
|
|
|
3,620
|
|
|
|
5,500
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net
|
|
|
593
|
|
|
|
631
|
|
|
Goodwill
|
|
|
2,341
|
|
|
|
2,507
|
|
|
Other intangible assets, net
|
|
|
516
|
|
|
|
649
|
|
|
Long-term investments
|
|
|
91
|
|
|
|
96
|
|
|
Other assets
|
|
|
251
|
|
|
|
283
|
|
|
Non-current assets of discontinued operations
|
|
|
—
|
|
|
|
1,165
|
|
|
Total assets
|
|
$
|
7,412
|
|
|
$
|
10,831
|
|
|
|
|
|
|
|
|
LIABILITIES AND EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
Accounts payable
|
|
$
|
261
|
|
|
$
|
302
|
|
|
Employee compensation and benefits
|
|
|
208
|
|
|
|
228
|
|
|
Deferred revenue
|
|
|
271
|
|
|
|
260
|
|
|
Other accrued liabilities
|
|
|
190
|
|
|
|
289
|
|
|
Current liabilities of discontinued operations
|
|
|
—
|
|
|
|
623
|
|
|
Total current liabilities
|
|
|
930
|
|
|
|
1,702
|
|
|
|
|
|
|
|
|
Long-term debt
|
|
|
1,656
|
|
|
|
1,663
|
|
|
Retirement and post-retirement benefits
|
|
|
176
|
|
|
|
209
|
|
|
Other long-term liabilities
|
|
|
489
|
|
|
|
522
|
|
|
Long-term liabilities of discontinued operations
|
|
|
—
|
|
|
|
1,434
|
|
|
Total liabilities
|
|
|
3,251
|
|
|
|
5,530
|
|
|
|
|
|
|
|
|
Total Equity:
|
|
|
|
|
|
Stockholders' equity:
|
|
|
|
|
|
Preferred stock; $0.01 par value; 125 million shares authorized;
none issued and outstanding
|
|
|
—
|
|
|
|
—
|
|
|
Common stock; $0.01 par value, 2 billion shares authorized; 610
million shares at April 30, 2015 and 608 million shares at October
31, 2014, issued
|
|
|
6
|
|
|
|
6
|
|
|
Treasury stock at cost; 277 million shares at April 30, 2015 and
273 million shares at October 31, 2014
|
|
|
(9,975
|
)
|
|
|
(9,807
|
)
|
|
Additional paid-in-capital
|
|
|
9,000
|
|
|
|
8,967
|
|
|
Retained earnings
|
|
|
5,397
|
|
|
|
6,466
|
|
|
Accumulated other comprehensive loss
|
|
|
(270
|
)
|
|
|
(334
|
)
|
|
Total stockholders' equity
|
|
|
4,158
|
|
|
|
5,298
|
|
|
Non-controlling interest
|
|
|
3
|
|
|
|
3
|
|
|
Total equity
|
|
|
4,161
|
|
|
|
5,301
|
|
|
Total liabilities and equity
|
|
$
|
7,412
|
|
|
$
|
10,831
|
|
|
|
|
|
|
The preliminary balance sheet is estimated based on our current
information.
|
|
|
|
|
|
Page 4
|
|
|
|
AGILENT TECHNOLOGIES, INC.
|
|
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
|
|
(In millions)
|
|
(Unaudited)
|
|
PRELIMINARY
|
|
|
|
|
|
|
|
Three Months
|
|
Six Months
|
|
|
|
Ended
|
|
Ended
|
|
|
|
April 30,
|
|
April 30,
|
|
|
|
|
2015
|
|
|
|
2015
|
|
|
Cash flows from operating activities:
|
|
|
|
|
|
Net income
|
|
$
|
83
|
|
|
$
|
155
|
|
|
|
|
|
|
|
|
Adjustments to reconcile net income to net cash provided by (used
in) operating activities:
|
|
|
|
|
|
Depreciation and amortization
|
|
|
63
|
|
|
|
131
|
|
|
Share-based compensation
|
|
|
11
|
|
|
|
33
|
|
|
Excess and obsolete inventory related charges
|
|
|
9
|
|
|
|
13
|
|
|
Other non-cash expenses, net
|
|
|
2
|
|
|
|
5
|
|
|
Changes in assets and liabilities:
|
|
|
|
|
|
Accounts receivable
|
|
|
31
|
|
|
|
16
|
|
|
Inventory
|
|
|
(13
|
)
|
|
|
(18
|
)
|
|
Accounts payable
|
|
|
4
|
|
|
|
(35
|
)
|
|
Employee compensation and benefits
|
|
|
27
|
|
|
|
(7
|
)
|
|
Other assets and liabilities
|
|
|
(34
|
)
|
|
|
(130
|
)
|
|
Net cash provided by operating activities (a) |
|
|
183
|
|
|
|
163
|
|
|
|
|
|
|
|
|
Cash flows from investing activities:
|
|
|
|
|
|
Investments in property, plant and equipment
|
|
|
(20
|
)
|
|
|
(52
|
)
|
|
Proceeds from sale of property, plant and equipment
|
|
|
11
|
|
|
|
11
|
|
|
Proceeds from divestiture
|
|
|
3
|
|
|
|
3
|
|
|
Payment to acquire equity method investment
|
|
|
(1
|
)
|
|
|
(1
|
)
|
|
Change in restricted cash and cash equivalents, net
|
|
|
—
|
|
|
|
1
|
|
|
Net cash used in investing activities
|
|
|
(7
|
)
|
|
|
(38
|
)
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
Issuance of common stock under employee stock plans
|
|
|
32
|
|
|
|
40
|
|
|
Treasury stock repurchases
|
|
|
(162
|
)
|
|
|
(168
|
)
|
|
Payment of dividends
|
|
|
(33
|
)
|
|
|
(67
|
)
|
|
Net transfer (to) from Keysight
|
|
|
62
|
|
|
|
(734
|
)
|
|
Net cash used in financing activities
|
|
|
(101
|
)
|
|
|
(929
|
)
|
|
|
|
|
|
|
|
Effect of exchange rate movements
|
|
|
4
|
|
|
|
(27
|
)
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
79
|
|
|
|
(831
|
)
|
|
|
|
|
|
|
|
Change in cash and cash equivalents within current assets of
discontinued operations
|
|
|
—
|
|
|
|
810
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at beginning of period
|
|
|
2,118
|
|
|
|
2,218
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period
|
|
$
|
2,197
|
|
|
$
|
2,197
|
|
|
|
|
|
|
|
|
(a) Cash payments included in operating activities:
|
|
|
|
|
|
Severance payments
|
|
|
16
|
|
|
|
23
|
|
|
Income tax payments, net
|
|
|
6
|
|
|
|
79
|
|
|
|
|
|
|
The preliminary cash flow is estimated based on our current
information.
|
|
|
|
|
|
Page 5
|
|
|
|
NON-GAAP INCOME FROM CONTINUING OPERATIONS AND DILUTED EPS
RECONCILIATIONS
|
|
(In millions, except per share amounts)
|
|
(Unaudited)
|
|
PRELIMINARY
|
|
|
|
|
|
|
|
Three Months Ended
|
|
Six Months Ended
|
|
|
|
April 30,
|
|
April 30,
|
|
|
|
|
2015
|
|
|
Diluted EPS
|
|
|
2014
|
|
Diluted EPS
|
|
|
2015
|
|
|
Diluted EPS
|
|
|
2014
|
|
|
Diluted EPS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Income from continuing operations
|
|
$
|
88
|
|
|
$
|
0.26
|
|
|
$
|
40
|
|
$
|
0.12
|
|
$
|
190
|
|
|
$
|
0.56
|
|
|
$
|
161
|
|
|
$
|
0.48
|
|
|
Non-GAAP adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring and other related costs
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
—
|
|
|
|
(2
|
)
|
|
|
(0.01
|
)
|
|
Acceleration of share-based compensation related to workforce
reduction
|
|
|
1
|
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
2
|
|
|
|
0.01
|
|
|
|
—
|
|
|
|
—
|
|
|
Intangible amortization
|
|
|
38
|
|
|
|
0.11
|
|
|
|
49
|
|
|
0.14
|
|
|
81
|
|
|
|
0.24
|
|
|
|
98
|
|
|
|
0.29
|
|
|
Business exit and divestiture costs
|
|
|
10
|
|
|
|
0.03
|
|
|
|
—
|
|
|
—
|
|
|
13
|
|
|
|
0.04
|
|
|
|
—
|
|
|
|
—
|
|
|
Transformational initiatives
|
|
|
17
|
|
|
|
0.05
|
|
|
|
8
|
|
|
0.02
|
|
|
29
|
|
|
|
0.09
|
|
|
|
11
|
|
|
|
0.03
|
|
|
Acquisition and integration costs
|
|
|
1
|
|
|
|
—
|
|
|
|
2
|
|
|
0.01
|
|
|
2
|
|
|
|
0.01
|
|
|
|
8
|
|
|
|
0.02
|
|
|
Pre-separation costs
|
|
|
—
|
|
|
|
—
|
|
|
|
2
|
|
|
0.01
|
|
|
—
|
|
|
|
—
|
|
|
|
4
|
|
|
|
0.01
|
|
|
Unallocated corporate costs
|
|
|
—
|
|
|
|
—
|
|
|
|
10
|
|
|
0.03
|
|
|
—
|
|
|
|
—
|
|
|
|
20
|
|
|
|
0.06
|
|
|
Other
|
|
|
(2
|
)
|
|
|
(0.01
|
)
|
|
|
2
|
|
|
0.01
|
|
|
(1
|
)
|
|
|
—
|
|
|
|
3
|
|
|
|
0.01
|
|
|
Adjustment for taxes (a) |
|
|
(24
|
)
|
|
|
(0.06
|
)
|
|
|
6
|
|
|
0.01
|
|
|
(48
|
)
|
|
|
(0.15
|
)
|
|
|
(44
|
)
|
|
|
(0.12
|
)
|
|
Non-GAAP Income from continuing operations
|
|
$
|
129
|
|
|
$
|
0.38
|
|
|
$
|
119
|
|
$
|
0.35
|
|
$
|
268
|
|
|
$
|
0.80
|
|
|
$
|
259
|
|
|
$
|
0.77
|
|
|
|
|
(a) The adjustment for taxes excludes tax benefits that
management believes are not directly related to ongoing operations
and which are either isolated or cannot be expected to occur again
with any regularity or predictability. For the three and six
months ended April 30, 2015 and 2014, management uses a non-GAAP
effective tax rate of 20% and 16%, respectively, that we believe
to be indicative of on-going operations.
|
|
|
|
Historical amounts are reclassified to conform with current
presentation.
|
|
|
|
We provide non-GAAP income from continuing operations and non-GAAP
income from continuing operations per share amounts in order to
provide meaningful supplemental information regarding our
operational performance and our prospects for the future. These
supplemental measures exclude, among other things, charges related
to the amortization of intangibles, the impact of restructuring
charges, transformational initiatives, acquisition and integration
costs, business exit and divestiture and pre-separation costs. Some
of the exclusions, such as impairments, may be beyond the control of
management. Further, some may be less predictable than revenue
derived from our core businesses (the day to day business of selling
our products and services). These reasons provide the basis for
management's belief that the measures are useful.
|
|
|
|
Restructuring costs include incremental expenses incurred
in the period associated with publicly announced major
restructuring programs, usually aimed at material changes in
business and/or cost structure. Such costs may include one-time
termination benefits, asset impairments, facility-related costs
and contract termination fees.
|
|
|
|
Transformational initiatives include expenses incurred in the
period associated with targeted cost reduction activities such as
manufacturing transfers, small site consolidations, reorganizations,
insourcing or outsourcing of activities. Such costs may include move
and relocation costs, one-time termination benefits and other
one-time reorganization costs.
|
|
|
|
Acquisition and Integration costs include all incremental
expenses incurred to effect a business combination which have been
expensed during the period. Such acquisition costs may include
advisory, legal, accounting, valuation, and other professional or
consulting fees. Such integration costs may include expenses
directly related to integration of business and facility operations,
information technology systems and infrastructure and other
employee-related costs.
|
|
|
|
Pre-separation costs include Agilent-specific incremental
expenses incurred in order to effect the separation, through
November 1, 2014 distribution date.
|
|
|
|
Business exit and divestiture costs include costs associated
with the exit of the NMR business and the divestiture of the XRD
business.
|
|
|
|
Our management uses non-GAAP measures to evaluate the performance of
our core businesses, to estimate future core performance and to
compensate employees. Since management finds this measure to be
useful, we believe that our investors benefit from seeing our
results “through the eyes” of management in addition to seeing our
GAAP results. This information facilitates our management’s internal
comparisons to our historical operating results as well as to the
operating results of our competitors.
|
|
|
|
Our management recognizes that items such as amortization of
intangibles and restructuring charges can have a material impact
on our cash flows and/or our net income. Our GAAP financial
statements including our statement of cash flows portray those
effects. Although we believe it is useful for investors to see
core performance free of special items, investors should
understand that the excluded items are actual expenses that may
impact the cash available to us for other uses. To gain a complete
picture of all effects on the company’s profit and loss from any
and all events, management does (and investors should) rely upon
the GAAP income statement. The non-GAAP numbers focus instead upon
the core business of the company, which is only a subset, albeit a
critical one, of the company’s performance.
|
|
|
|
Readers are reminded that non-GAAP numbers are merely a supplement
to, and not a replacement for, GAAP financial measures. They should
be read in conjunction with the GAAP financial measures. It should
be noted as well that our non-GAAP information may be different from
the non-GAAP information provided by other companies.
|
|
|
|
|
|
The preliminary non-GAAP net income and diluted EPS reconciliation
is estimated based on our current information.
|
|
|
|
|
|
Page 6
|
|
|
|
AGILENT TECHNOLOGIES, INC.
|
|
SEGMENT INFORMATION
|
|
(In millions, except where noted)
|
|
(Unaudited)
|
|
PRELIMINARY
|
|
|
|
|
|
Life Sciences and Applied Markets Group
|
|
|
|
|
|
|
|
|
|
Q2'15
|
|
Q2'14
|
|
Q1'15
|
|
Orders
|
|
$
|
506
|
|
|
$
|
502
|
|
|
$
|
488
|
|
|
Revenue
|
|
$
|
473
|
|
|
$
|
495
|
|
|
$
|
547
|
|
|
Gross Margin, %
|
|
|
56.1
|
%
|
|
|
54.4
|
%
|
|
|
56.1
|
%
|
|
Income from Operations
|
|
$
|
75
|
|
|
$
|
71
|
|
|
$
|
107
|
|
|
Operating margin, %
|
|
|
15.8
|
%
|
|
|
14.2
|
%
|
|
|
19.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diagnostics and Genomics Group
|
|
|
|
|
|
|
|
|
|
Q2'15
|
|
Q2'14
|
|
Q1'15
|
|
Orders
|
|
$
|
168
|
|
|
$
|
175
|
|
|
$
|
158
|
|
|
Revenue
|
|
$
|
169
|
|
|
$
|
168
|
|
|
$
|
148
|
|
|
Gross Margin, %
|
|
|
54.8
|
%
|
|
|
57.8
|
%
|
|
|
48.9
|
%
|
|
Income from Operations
|
|
$
|
25
|
|
|
$
|
26
|
|
|
$
|
1
|
|
|
Operating margin, %
|
|
|
15.0
|
%
|
|
|
15.2
|
%
|
|
|
0.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Agilent CrossLab™ Group
|
|
|
|
|
|
|
|
|
|
Q2'15
|
|
Q2'14
|
|
Q1'15
|
|
Orders
|
|
$
|
365
|
|
|
$
|
354
|
|
|
$
|
349
|
|
|
Revenue
|
|
$
|
321
|
|
|
$
|
325
|
|
|
$
|
331
|
|
|
Gross Margin, %
|
|
|
49.6
|
%
|
|
|
47.9
|
%
|
|
|
50.1
|
%
|
|
Income from Operations
|
|
$
|
69
|
|
|
$
|
70
|
|
|
$
|
68
|
|
|
Operating margin, %
|
|
|
21.5
|
%
|
|
|
21.5
|
%
|
|
|
20.7
|
%
|
|
|
|
Income from operations reflect the results of our reportable
segments under Agilent's management reporting system which are not
necessarily in conformity with GAAP financial measures. Income from
operations of our reporting segments exclude, among other things,
charges related to the amortization of intangibles, the impact of
restructuring charges, transformational initiatives, acquisition and
integration costs, business exit and divestiture and pre-separation
costs.
|
|
|
|
In general, recorded orders represent firm purchase commitments from
our customers with established terms and conditions for products and
services that will be delivered within six months.
|
|
|
|
Readers are reminded that non-GAAP numbers are merely a supplement
to, and not a replacement for, GAAP financial measures. They should
be read in conjunction with the GAAP financial measures. It should
be noted as well that our non-GAAP information may be different from
the non-GAAP information provided by other companies.
|
|
|
|
|
|
The preliminary segment information is estimated based on our
current information.
|
|
|
|
|
|
Page 7
|
|
|
|
AGILENT TECHNOLOGIES, INC.
|
|
RECONCILIATIONS OF REVENUE BY SEGMENT EXCLUDING THE IMPACT OF
CURRENCY ADJUSTMENTS (CORE)
|
|
(in millions)
|
|
(Unaudited)
|
|
PRELIMINARY
|
|
|
|
|
|
|
|
Year-over-Year
|
|
|
|
|
|
|
|
GAAP
|
|
Currency Adjustments (a)
|
|
Currency-Adjusted
|
|
|
|
|
|
|
|
Year-over-Year
|
|
|
|
|
|
|
|
Year-over-Year
|
|
Revenue by Segment
|
|
Q2'15
|
|
Q2'14
|
|
% Change
|
|
Q2'15
|
|
Q2'15
|
|
Q2'14
|
|
% Change
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Life Sciences and Applied Markets Group
|
|
$
|
473
|
|
$
|
495
|
|
-5
|
%
|
|
$
|
(27
|
)
|
|
$
|
500
|
|
$
|
495
|
|
1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diagnostics and Genomics Group
|
|
|
169
|
|
|
168
|
|
1
|
%
|
|
|
(16
|
)
|
|
|
185
|
|
|
168
|
|
10
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Agilent CrossLab™ Group
|
|
|
321
|
|
|
325
|
|
-1
|
%
|
|
|
(26
|
)
|
|
|
347
|
|
|
325
|
|
7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Agilent
|
|
$
|
963
|
|
$
|
988
|
|
-3
|
%
|
|
$
|
(69
|
)
|
|
$
|
1,032
|
|
$
|
988
|
|
4
|
%
|
|
|
|
(a) We compare the year-over-year change in revenue
excluding the effect of foreign currency rate fluctuations to assess
the performance of our underlying business. To determine the impact
of currency fluctuations, current period results for entities
reporting in currencies other than United States dollars are
converted into United States dollars at the actual exchange rate in
effect during the respective prior periods.
|
|
|
|
|
|
The preliminary reconciliation of GAAP revenue adjusted for the
impact of currency is estimated based on our current information.
|
|
|
|
|
|
Page 8
|
|
|
|
AGILENT TECHNOLOGIES, INC.
|
|
RECONCILIATION OF ADJUSTED NON-GAAP INCOME FROM OPERATIONS AND
OPERATING MARGINS
|
|
(In millions, except margin data)
|
|
(Unaudited)
|
|
PRELIMINARY
|
|
|
|
|
|
|
|
Operating
|
|
|
|
Q2 2015
|
|
Margin %
|
|
|
|
|
|
|
|
Revenue:
|
|
$
|
963
|
|
|
|
|
|
|
|
|
|
|
Income from operations:
|
|
|
|
|
|
GAAP Income from operations
|
|
$
|
107
|
|
|
|
|
Add:
|
|
|
|
|
|
Amortization of intangible assets
|
|
|
38
|
|
|
|
|
Transformational programs
|
|
|
17
|
|
|
|
|
Acquisition and integration costs
|
|
|
1
|
|
|
|
|
Business exit and divestiture costs
|
|
|
8
|
|
|
|
|
Acceleration of share-based compensation expense
|
|
|
1
|
|
|
|
|
Other
|
|
|
(3
|
)
|
|
|
|
Non-GAAP income from operations
|
|
$
|
169
|
|
|
17.6
|
%
|
|
Reimbursement from Keysight for services (a) |
|
|
7
|
|
|
|
|
Adjusted non-GAAP income from operations
|
|
$
|
176
|
|
|
18.3
|
%
|
|
|
|
(a) Post separation, Agilent is providing Keysight Technologies,
Inc. certain IT and site services. These IT and site services are
included in our operating expenses. The amounts billed to Keysight
for these services are recorded in other income.
|
|
|
|
We provide non-GAAP income from operations in order to provide
meaningful supplemental information regarding our operational
performance and our prospects for the future. These supplemental
measures exclude, among other things, charges related to the
amortization of intangibles, transformational initiatives,
acquisition and integration costs and business exit and divestiture
costs. Some of the exclusions, such as impairments, may be beyond
the control of management. Further, some may be less predictable
than revenue derived from our core businesses (the day to day
business of selling our products and services). These reasons
provide the basis for management's belief that the measures are
useful.
|
|
|
|
Our management recognizes that items such as amortization of
intangibles and restructuring charges can have a material impact on
our cash flows and/or our net income. Our GAAP financial statements
including our statement of cash flows portray those effects.
Although we believe it is useful for investors to see core
performance free of special items, investors should understand that
the excluded items are actual expenses that may impact the cash
available to us for other uses. To gain a complete picture of all
effects on the company’s profit and loss from any and all events,
management does (and investors should) rely upon the GAAP income
statement. The non-GAAP numbers focus instead upon the core business
of the company, which is only a subset, albeit a critical one, of
the company’s performance.
|
|
|
|
Readers are reminded that non-GAAP numbers are merely a supplement
to, and not a replacement for, GAAP financial measures. They should
be read in conjunction with the GAAP financial measures. It should
be noted as well that our non-GAAP information may be different from
the non-GAAP information provided by other companies.
|
|
|
|
|
|
The preliminary reconciliation of income from operations and
operating margins is estimated based on our current information.
|
|
|
|
|
|
Page 9
|

View source version on businesswire.com: http://www.businesswire.com/news/home/20150518006552/en/
Source: Agilent Technologies Inc.
Agilent Technologies Inc.
EDITORIAL CONTACT:
Michele Drake, +1
408-345-8396
michele_drake@agilent.com
or
INVESTOR
CONTACT:
Alicia Rodriguez, +1 408-345-8948
alicia_rodriguez@agilent.com